Last reviewed · How we verify
ProAir® HFA
ProAir HFA is a short-acting beta-2 adrenergic agonist that relaxes airway smooth muscle to rapidly relieve bronchospasm and improve airflow in the lungs.
ProAir HFA is a short-acting beta-2 adrenergic agonist that relaxes airway smooth muscle to rapidly relieve bronchospasm and improve airflow in the lungs. Used for Acute relief of bronchospasm in patients with reversible obstructive airway disease, Prevention of exercise-induced bronchospasm.
At a glance
| Generic name | ProAir® HFA |
|---|---|
| Also known as | ProAir®, albuterol, albuterol HFA-MDI |
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Drug class | Short-acting beta-2 agonist (SABA) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
The drug works by binding to beta-2 adrenergic receptors on airway smooth muscle cells, triggering a cascade that increases intracellular cAMP levels and causes muscle relaxation. This leads to rapid bronchodilation, making it effective for acute relief of asthma symptoms and prevention of exercise-induced bronchoconstriction. The HFA formulation uses hydrofluoroalkane propellant instead of chlorofluorocarbon.
Approved indications
- Acute relief of bronchospasm in patients with reversible obstructive airway disease
- Prevention of exercise-induced bronchospasm
Common side effects
- Tremor
- Nervousness
- Headache
- Palpitations
- Muscle cramps
- Tachycardia
Key clinical trials
- Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (PHASE3)
- Clinical Assessment of Acupuncture for the Treatment of Chronic Asthma (NA)
- Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087) (PHASE3)
- The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic Asthma (0476-388) (PHASE1)
- Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574) (PHASE2)
- Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients (PHASE2)
- Albuterol HFA MDI in Pediatric Participants With Asthma (PHASE3)
- A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ProAir® HFA CI brief — competitive landscape report
- ProAir® HFA updates RSS · CI watch RSS
- Teva Branded Pharmaceutical Products R&D, Inc. portfolio CI